Table 2 Demographic and clinical characteristics of renal transplant recipients and incidence of JC virus

Age, mean (SD)

49.07 (15.01)

47.78 (15.40)

0.701

47.37 (14.87)

48.21(15.40)

0.827*

Sex

 Female

6 (10.9)

49 (89.1)

0.005

8 (14.5)

47 (85.5)

0.722^#

 Male

20 (30.7)

45 (69.2)

12 (18.4)

53 (81.5)

Immunosuppression regimen

 Sirolimus

1 (25.0)

3 (75.0)

0.903

0 (0.0)

4 (100.0)

0.236^#

 Mycophenolate Mofetil

19 (23.5)

62 (76.5)

0.718

11 (13.6)

70 (86.4)

0.330^#

 Cyclosporine

12 (25.0)

36 (75.0)

0.592

7 (14.6)

41 (85.4)

0.759^#

 Tacrolimus

3 (17.6)

14 (82.4)

0.605

3 (17.6)

14 (82.4)

0.825^#

 Mycophenolic acid

3 (20.0)

12 (80.0)

0.804

2 (13.3)

13 (86.7)

0.777^#

 Azathioprine

0 (0.0)

2 (100.0)

0.310

0 (0.0)

2 (100.0)

0.404^#

 Prednisolone acetate

27 (24.1)

85 (75.9)

0.039

20 (17.9)

92 (82.0)

0.091^#

 CR, mean (SD)

1.66 (2.10)

1.41 (0.68)

0.329

1.93 (2.55)

1.38 (0.611)

0.365*

 GFR, mean (SD)

63.30 (18.34)

69.19 (27.97)

0.202

70.16 (26.16)

67.44 (26.27)

0.679*

 Duration post-transplantation

8 (4.97)

10.47 (6.65)

0.041

7.21 (4.96)

10.42 (6.50)

0.020*

Diseases

 Diabetes

3 (42.9)

4 (57.1)

0.216

4 (57.1)

3 (42.9)

0.002^#

 High blood pressure

5 (41.7)

7 (58.3)

0.116

1 (8.3)

11 (91.7)

0.420^#

 Glomerulonephritis

2 (25.0)

6 (75.0)

0.862

0 (0.0)

8 (100.0)

0.091^#

 Alport syndrome

2 (40.0)

3 (60.0)

0.370

0 (0.0)

5 (100.0)

0.184^#

 Nephrotic syndrome

26 (23.0)

87 (77.0)

0.722

1 (16.7)

5 (83.3)

0.840^#

 Renal stone

1 (33.3)

2 (66.7)

0.664

2 (66.7)

1 (33.3)

0.015^#

 Polycystic renal

(20.0)

8 (80.0)

0.841

0 (0.0)

10 (100.0)

0.507^#

 Urinary reflux

2 (33.3)

4 (66.7)

0.533

1 (16.7)

5 (83.3)

0.955^#

 BK virus co-existence

4 (15.4%)

11 (11.7%)

0.415

6 (31.6%)

11 (10.9%)

0.029^#